

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
39091	15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	Number Agreed	4	4	Date Agreed	01/07/2017	4	19/10/2018	4	Recruitment Finished	
39092	16/EM/0167	179908	RESP 4602	Number Agreed	3	3	Date Agreed	31/01/2019	1	16/07/2018	1	Withdrawn By Sponsor	Sponsor closed recruitment early.
39093	15/WS/0170	184797	HAEM 4528	Number Agreed	4	4	Date Agreed	19/01/2019	7	07/09/2018	7	Recruitment Finished	
39094	15/EM/0500	188865	RESP 4446	Number Agreed	2	2	Date Agreed	20/09/2017	0	20/09/2018	0	Recruitment Finished	Participants sought, none identified within time frame.
39096	17/LO/0441	222471	MK-3475-604 (Phase 3 trial of etoposide/platinum with or without pembrolizumab)	Number Agreed	4	4	Date Agreed	30/09/2021	1	09/07/2018	1	Withdrawn By Sponsor	Sponsor closed recruitment early.
39097	17/NE/0151	223815	SGI-110 vs Treatment Choice in Adults with Previously Treated AML	Number Agreed	2	2	Date Agreed	29/09/2018	3	17/09/2018	3	Withdrawn By Sponsor	Sponsor closed recruitment early.
39098	16/LO/1709	212830	Semaglutide in NASH	Number Agreed	2	2	Date Agreed	19/11/2018	0	19/07/2018	0	Withdrawn By Sponsor	Sponsor closed recruitment early.
39099	18/SC/0098	241440	Subcut Daratumumab in combination with standard treatment regimens	Number Agreed	3	3	Date Agreed	27/10/2020	5	22/08/2018	5	Withdrawn By Sponsor	Sponsor closed recruitment early.
39100	18/NE/0200	244356	VX17-445-102 Efficacy and Safety of VX-445/TEZ/IVA in CF Het-min	Number Agreed	3	3	Date Agreed	30/06/2019	2	02/11/2018	2	Withdrawn By Sponsor	Sponsor closed recruitment early.
39101	18/NE/0201	244419	VX17-445-103 Efficacy and Safety of VX-445/TEZ/IVA in CF Homozygous	Number Agreed	3	3	Date Agreed	31/01/2019	2	02/11/2018	2	Withdrawn By Sponsor	Sponsor closed recruitment early.
39102	17/NW/0656	235797	ODYSSEY LEGACY.	Number Agreed	21	21	Date Agreed	31/12/2018	16	05/09/2018	16	Withdrawn By Sponsor	Sponsor faced challenges with trial, and so withdrew the trial internationally.
39103	18/LO/1002	242654	Study of GSK2857196 in pts. with RRMM who have failed on Daratumumab	Number Agreed	2	2	Date Agreed	07/12/2018	1	19/10/2018	1	Withdrawn By Sponsor	Sponsor closed recruitment early.
39104	18/HRA/1748	243170	Venetoclax (ABT-199)	Number Agreed	3	3	Date Agreed	06/08/2018	3	06/08/2018	3	Recruitment Finished	
39105	17/EM/0060	215678	Protocol I1F-MC-RHBY	Number Agreed	1	1	Date Agreed	01/01/2019	1	01/01/2019	1	Recruitment Finished	
39106	17/EE/0204	207238	BCX7353 as a treatment for acute HAE attacks	Number Agreed	3	3	Date Agreed	01/09/2018	4	17/10/2018	4	Recruitment Finished	
39107	18/NW/0507	250276	A Phase 1/2 Study of VX-121 in Subjects With Cystic Fibrosis and in Subjects without Cystic Fibrosis	Number Agreed	1	1	Date Agreed	13/02/2019	2	13/02/2019	2	Recruitment Finished	
39108	13/ES/0005	114717	NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC) / AZA-MDS-003	Number Agreed	3	3	Date Agreed	31/07/2020	1	27/07/2018	1	Withdrawn By Sponsor	Sponsor closed recruitment early.
39109	16/EM/0312	205489	Safety And Efficacy Of Orally Administered DS102 In NAFLD Patients	Number Agreed	5	5	Date Agreed	30/06/2018	4	27/07/2018	4	Recruitment Finished	Participants sought, 4 identified within time frame.
39110	17/EE/0074	217180	Lorlatinib (PF-06463922) Open Label Lung Cancer Study	Number Agreed	2	2	Date Agreed	31/10/2018	1	01/02/2019	1	Recruitment Finished	Participants sought, 1 identified within time frame.
39111	16/EE/0071	193751	Unravel MGUS	Number Agreed	100	100	Date Agreed	01/02/2019	66	28/02/2019	66	Recruitment Finished	Participants sought, 66 identified within time frame.
39112	17/SW/0279	231649	MO39171 - Atezolizumab in locally advanced or metastatic NSCLC	Number Agreed	6	6	Date Agreed	30/04/2019	4	08/11/2018	4	Withdrawn By Sponsor	Sponsor closed recruitment early.
39113	18/YH/0069	242258	GLOW study	Number Agreed	2	2	Date Agreed	03/03/2019	1	16/01/2019	1	Withdrawn By Sponsor	Sponsor closed recruitment early.
39114	17/LO/1103	230709	Research doses of BAY1817080 in healthy males & PoC in chronic cough pts	Number Agreed	2	2	Date Agreed	31/01/2019	1	31/01/2019	1	Recruitment Finished	Participants sought, 1 identified within time frame, phase 1 study and patients required to come in weekly.
39115	18/EM/0228	248988	Anti-viral effect of PC786 on RSV infection in HSCT recipients	Number Agreed	3	3	Date Agreed	31/08/2019	0	08/03/2019	0	Withdrawn By Sponsor	Sponsor closed recruitment early.
39126	17/EM/0063	213979	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study)	Number Agreed	2	2	Date Agreed	23/05/2019	4	23/05/2019	4	Recruitment Finished	
39127	17/NI/0096	225743	HOPE-1	Number Agreed	2	2	Date Agreed	28/02/2019	2	22/05/2019	2	Recruitment Finished	
39128	17/YH/0369	232340	BGB-3111-304	Number Agreed	2	2	Date Agreed	30/04/2019	3	09/05/2019	3	Recruitment Finished	
39129	17/NI/0128	223148	ALPHA-PE	Number Agreed	110	110	Date Agreed	30/03/2018	111	30/03/2019	111	Recruitment Finished	
39130	17/EM/0425	236800	Retrospective review of current treatment pathways for MF in the UK	Number Agreed	15	15	Date Agreed	31/01/2018	19	12/07/2018	19	Recruitment Finished	
39131	17/YH/0432	236091	GSK3772847 in participants with Asthma with AFAD	Number Agreed	3	3	Date Agreed	28/06/2019	1	20/06/2019	1	Withdrawn By Sponsor	Sponsor closed recruitment early.